IL1B and neoplasm: The anti-tumor efficacy of this Lipid A has previously been demonstrated in several models of tumors [147,148,149] and was dependent on cytokine secretion (IFNγ, IL-1β and TNFα), iNOS activation and tumor-associated neutrophil (TAN) reprogramming into anti-tumorigenic N1 [149,150].